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“One thing I have learned in a long life: that all our science, 
measured against reality, is primitive and childlike -- and yet it 
is the most precious thing we have.”   
Albert Einstein
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ABSTRACT 
Aortic valve calcification (AVC) or thickening is found in around one fifth of the general 
population between 65-75 years of age and increasingly thereafter. The process of aortic valve 
thickening and calcification is not only an aging (wear and tear) process of the valve leaflets. It is now 
considered to be closely related to atherosclerosis. The presence and the degree of AVC have been 
shown to have prognostic value in patients with cardiovascular diseases and in the general population. 
Despite its importance, there is no widely agreed upon scoring system that objectively quantifies AVC. 
The aim of this project was to investigate different methods for evaluating AVC, using 
transthoracic and transoesophageal echocardiography (TTE and TOE), intra-operative assessment of 
the valve (IOS) and ex vivo evaluation based on computed tomography (CT) of the excised aortic 
valves and based on valve weight. A 5-grade scoring system was used for the visual assessment of 
AVC on real-time and still TTE and TOE images of the aortic valve, as well as intra-operatively. 
Computer-based greyscale measurement (GSM) software was used to obtain a quantitative-ultrasound-
based AVC measure, which was compared with the visual AVC score from TTE and TOE, whereas 
IOS was used as the gold-standard method. We also aimed at identifying the most suitable ex vivo 
conditions and CT parameters for optimal AVC scanning by CT in a calcium hydroxyapatite (CaHA) 
phantom study. The TTE and TOE AVC scores and IOS were compared to the weight and the CT 
CaHA mineral mass (MM) index of the explanted aortic valves. The study cohorts were recruited 
among patients undergoing aortic valve replacement because of aortic valve disease and/or ascending 
aorta aneurysm. 
In Study I, which included 185 patients, we showed that the visual evaluation of AVC using 
real-time TTE images yielded better correlations with IOS than did quantitative still frame measures 
based on GSM (r = 0.83 vs 0.64, respectively). In Study II, AVC scores based on TTE and TOE real-
time images from 169 patients showed strong correlations with IOS (r = 0.83 and 0.82, respectively). 
GSM-based measures correlated less well with IOS, even for TOE (r = 0.52). In Study II, we also 
showed that TOE was more accurate than TTE in diagnosing the aortic valve phenotype. In the CT-
phantom-based, methodological Study III, we identified optimal CT scanning and reconstruction 
parameters, as well as the most suitable medium (normal saline) for ex vivo tissue CT-based calcium 
scoring. In Study IV, 155 operatively explanted aortic valves were weighed and scanned ex vivo by 
CT, and CaHA MM was measured. The CaHA MM exhibited a strong correlation with valve weight (r 
= 0.91), whereas AVC scores based on TTE, TOE and IOS showed weaker correlations. Conversely, 
echocardiographic and intra-operative AVC evaluation showed a better correlation with 
haemodynamic parameters compared with ex vivo CT AVC scoring. 
 In conclusion, real-time echocardiographic images are crucial for accurate AVC scoring, 
regardless of whether TTE or TOE is used. Echocardiographic AVC scoring was as accurate as intra-
operative assessment, according to valve weight and ex vivo CT. For ex vivo calcium scoring by CT, 
in addition to scanning and reconstruction parameters, using saline as the surrounding medium seems 
to be important. TOE is more accurate than TTE in detecting the bicuspid aortic valve.
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SAMMANFATTNING
Aortaklaff-förkalkning (AVC) eller förtjockning förekommer hos ungefär en femtedel av 
befolkningen mellan 65-75 års ålder och ökar därefter. Förtjockning och förkalkning av aortaklaffen 
är inte bara degenerativa åldersförändringar. Senare rön har visat att det sannolikt finns en koppling 
mellan AVC och åderförkalkningssjukdom, med inflammation som en viktig gemensam faktor.
Förekomst och grad av AVC har visat sig ha prognostisk betydelse hos patienter med 
hjärtkärlsjukdomar och i befolkningen generellt. Trots dess prognostiska värde finns det inga allmänt 
accepterade graderingsmetoder för AVC.
Syftet med denna avhandling var att på ett metodologiskt sätt utvärdera olika verktyg för 
gradering av AVC vid transthorakal (TTE) och transoesophageal (TOE) ekokardiografisk avbildning 
av aortaklaffen, i jämförelse med direkt intraoperativ kirurgisk bedömning (IOS) samt
datortomografisk undersökning (CT) och vikt av bortopererade aortaklaffar. En 5-gradig 
skattningsskala användes för visuell bedömning av AVC på realtids- och stillbilder av aortaklaffen 
från TTE och TOE, samt intraoperativ kirurgisk bedömning. Programvara för datorbaserad 
gråskalemätning (GSM) användes för att erhålla en kvantitativ-ultraljudsbaserad AVC skattning som 
jämfördes med den visuella bedömningen av TTE och TOE, samt IOS som referensmetod. Vi ville 
identifiera lämpligaste ex vivo förhållanden och CT parametrar för optimal kalkbedömning med hjälp 
av CT i en experimentell studie av kalcium-hydroxyapatit (CaHA). AVC grad bedömd med TTE och 
TOE jämfördes med IOS, vikt och CT mätning av kalk i uttagna aortaklaffar. Studien omfattade 
patienter som genomgick klaffbyte på grund av aortaklaffsjukdom. I studie I, som omfattade 185 
patienter, visade vi att visuell utvärdering av AVC med realtids TTE stämde bättre (r = 0,83) med IOS 
än mätning av gråskala i stillbilder (r =0,64). I studie II visades att AVC bedöming av rörliga TOE
bilder från 169 patienter korrelerade väl med IOS (r = 0,83). GSM i stillbild korrelerade mindre bra 
med IOS, även för TOE (r = 0,52). I studie II visade vi också att TOE var mer exakt än TTE i att 
avgöra om aortaklaffen har två eller tre klaffblad (är bi- eller tricuspid; BAV eller TAV). I den CT-
fantom-baserade studien III försökte vi identifiera optimala CT parametrar samt det mest lämpliga 
omgivande mediet (fysiologisk koksaltlösning) för CT-baserad kalkgradering av små preparat. I studie 
IV, vägdes och gjordes CT av 155 operativt uttagna aortaklaffar. CT mätning av klaffkalk korrelerade 
starkt till klaffvikt (r = 0,91), medan AVC skattning baserad på TTE, TEE och IOS visade svagare 
samband. Omvänt visade ekokardiografisk och intraoperativ AVC utvärdering en bättre korrelation 
med hemodynamiska parametrar relaterade till aortaklaffsjukdom, jämfört med CT. 
Sammanfattningsvis, rörliga ekokardiografiska bilder är nödvändiga för noggrann 
bedömning av klaffkalk, oavsett om TTE eller TOE används. Ekokardiografisk kalkbedömning var 
lika exakt som intraoperativ bedömning, enligt klaffvikt och ex vivo CT. För CT mätning av kalk i 
uttagna klaffar synes, förutom CT parameterar, fysiologisk koksaltlösning viktig som omgivande 
medium. TOE är mer exakt än TTE för att detektera bicuspid aortaklaff.
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LIST OF ABBREVIATIONS 
ACE Angiotensin-converting enzyme
AMS Artery measurement system
AR Aortic regurgitation
ARBs Angiotensin receptor blockers
AS Aortic stenosis
ASAP Advanced study of aortic pathology
AVA Aortic valve area
AVC Aortic valve calcification
AVR Aortic valve replacement
BAV Bicuspid aortic valve
BMP Bone morphogenic protein
CAD Coronary artery disease
CaHA Calcium hydroxyapatite
CT Computed tomography
CV Coefficient of variation
DES Drug-eluting stents
EBCT Electron beam computed tomography
EC Endothelial cells
GSM Greyscale measurement
GSMn Greyscale mean
hsCRP High sensitivity C-reactive protein
HU Hounsfield unit
ICC Intra-class correlation coefficient
IMT Intima–media thickness
IOS Intra-operative score (surgical score)
LDL Low density lipoprotein
LV Left ventricular
LVOT Left ventricular outflow tract
MAC Mitral annulus calcification
MM Mineral mass
MRI Magnetic resonance imaging
MSCT Multi-slice computed tomography
PET Positron emission tomography
PDA Patent ductus arteriosus
OCT optimum cutting temperature imbedding medium
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QRM Quantification of coronary calcium
RNA-later Ribonucleic acid stabilization and storage reagent solution
SPECT Single-photon emission computed tomography
STJ Sinotubular junction
SVS Still image AVC score
TAV Tricuspid aortic valve
TAVR Transcatheter aortic valve replacement
TGF-E Transforming growth factor beta
TOE Transoesophageal echocardiography
TTE Transthoracic echocardiography
VEGF Vascular endothelial growth factor
Vmax Peak velocity measured across the valve measure in metres per second (m/s)
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1 INTRODUCTION 
1.1 HISTORICAL NOTES
The Edwin Smith Papyrus, which has been dated to 1700 B.C., is considered as the 
oldest known medical document that describes accurately several different types of body 
injuries, diagnostic methods and treatments (Figure 1). This ancient document was written 
on a 15-ft-long papyrus scroll by a single unknown Egyptian writer who was trying to copy 
an older document dated from 2500 to 3000 B.C. The document, which was never finished 
and was never signed by the author, was intended to be a surgical text-book and included 
48 different types of surgical cases. It discussed in detail the sterilization of wounds and 
instruments, the use of bread moulds to improve healing, suturing, bone fixation and even 
surgical operations. Despite being aimed at surgery, the papyrus included the first ever 
known description of the function of some body organs, including the heart. The heart 
function was clearly described as pumping the blood in the blood vessels throughout the 
body to various organs, and not as producing blood, as was long thought in the ancient 
world. Moreover, it linked the heart-pumping function with peripheral pulsation. These 
facts were not firmly established until the 17th century, rendering this ancient surgical 
document the oldest discovered to date to note the actual function of the heart.1, 2
Figure 1.
A piece of the 4000-
year-old Edwin 
Smith Papyrus scroll, 
currently preserved 
in the rare books 
vault at the New 
York Academy of 
Medicine. 
Reused under “Fair 
use” conditions from 
the U.S. National 
Library of Medicine 
(http://archive.nlm.ni
h.gov/proj/ttp/smith_
home.html)
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Even Leonardo da Vinci (1452–1519), who studied and illustrated anatomy in an 
explicit way and worked in detail on the heart during his last years of life, never disputed the 
medieval idea of constant blood flow to the periphery via arteries and veins.3 However, he 
applied the knowledge of flow in widening canals, and to study blood flow through heart 
valves, he built a glass model of the aorta with cusps. Furthermore, he produced the first 
depiction of a bicuspid aortic valve.4
Regarding cardiac valve calcification, the first case of a calcified aortic valve was 
described by Rayger in 1697 (published by T. Bonet in 1700). Cowper noted in 1706 a man 
with dyspnoea and, at autopsy, petrified aortic leaflets “…in as much that they could not 
approach each other”; in 1829, Lanneac presented a clinical description of valve 
calcification.5 From the 1930s, further articles were published on this topic, and in 1949, 
Davies and Steiner provided an excellent historical overview, partially cited in the previous 
sentence, together with a study of 14 patients with “pure” calcified aortic valve.5 Those 
authors described their aetiology, clinical symptoms, physical signs and radiological findings. 
Even as early as the 1930s, researchers aimed at using Röntgen imaging to detect aortic and 
mitral valve calcifications.6 Several studies attempted to assess the association between the 
presence of cardiac valve calcification (mitral or aortic) and diet, lifespan and other cardiac 
pathologies.7
In the 1950s, the clinical need to determine the function of the mitral valve inspired 
Inge Edler – born in Malmö and head of the Department of Internal Medicine and director of 
the Cardiovascular Laboratory at the University of Lund for 10 years – to invent 
echocardiography.8, 9 He achieved this with the help of another young physicist, Carl 
Hellmuth Hertz.10 His primary aim was to rule out the presence of mitral regurgitation, which 
complicated commissurotomy of mitral stenosis. Based on the Siemens Ultrasound 
Reflectoscope (Ultraschall-Impulsgerät), the efforts of Edler and Hertz led to the first 
ultrasonic images of the moving heart, thus marking the dawn of echocardiography on 
October 29, 1953.8, 11, 12 The echocardiographic M-mode appearance of mitral annulus 
calcification was described in 1975.13
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1.2 AORTIC VALVE EMBRYOLOGY, ANATOMY AND FUNCTION
1.2.1 Embryology
Aortic valve formation starts in the 4th week of intra-uterine life, together with the 
appearance of the pulmonary valve (semilunar valve formation) (Figure 2). The process 
begins with the formation of two opposing cushions (the right dorsal and left ventral 
endocardial bulbar cushions) in the truncus arteriosus. The cushions fuse first at the 
truncoconal position, and then the fusion “zips” distally towards the outflow tract and 
proximally towards the ventricles. In addition, another two intercalated endocardial 
cushions develop at a right angle from the aforementioned cushions. This occurs as they 
spiral in a right-handed direction, leading to the pulmonary trunk and ending up anterior to 
the aorta.
The fusion of these cushions leads to the formation of the truncal septum, which 
undergoes differentiation to form two of the three aortic valve leaflets (right and left 
leaflets) and the two leaflets of the pulmonary valve. Subsequently, the previously formed 
right cushion forms the posterior (non-coronary) aortic valve leaflet, whereas the left 
cushion forms the anterior pulmonary valve leaflet. During this process, the truncus twists 
anti-clockwise and shifts caudally as the endocardial cushions differentiate, leading to 
mature valve leaflets. A normal aortic valve consists of three leaflets, i.e., a tricuspid aortic 
valve (TAV). Abnormal fusions or flaws in the aforementioned processes lead to 
anatomical congenital aortic and pulmonary valve anomalies.14, 15
Such anomalies include a congenital bicuspid aortic valve (BAV), which consists 
of only two cusps and is the most common congenital heart malformation.16 BAV can occur 
in isolation, it can be associated with other cardiovascular malformations (such as 
coarctation of the aorta, patent ductus arteriosus and cardiac septal defects) or it can be a 
part of a clinical syndrome (such as Turner and Williams–Beuren syndromes).17-22 The 
pathogenesis of BAV is multifactorial. Environmental factors have been suggested to cause 
the incorrect fusion of the leaflets.23 Studies showing increased risk of BAV in first-degree 
relatives and in families further support the genetic heritable nature of isolated BAV.20, 22
Studies performed in humans showed the association between the presence of isolated (non-
syndromatic) BAV and the transcription regulatory gene NOTCH1, which is located on
chromosome 9q34.24, 25 Several other genes have been suggested to contribute to BAV 
occurrence, based on animal studies, 26, 27 however, none of them showed this type of 
association in humans.28, 29 The dominant inheritance of cardiovascular defects associated 
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with BAV has been linked to chromosomes 18q, 13q and 5q; moreover, chromosome 15q25–
26 in BAV patients is associated with ascending aortic aneurysm.21, 30
Figure 2. Embryology of the aortic valve. Reprinted from the book “Review of Medical Embryology” 
by Ben Pansky MD PhD, 1982, with permission from The LifeMap Discovery Team 
http://discovery.lifemapsc.com 31
71.2.2 Normal aortic valve anatomy and function
Heart valves normally function to allow a unidirectional forward flow of the blood. 
Heart valves are in continuous motion throughout most of the cardiac cycle, thus requiring 
elasticity and strength to accomplish their function successfully and durably, as they 
withstand continuous stress and strain over the lifespan of an individual.32
The aortic valve is found at the junction between the left ventricular outflow tract 
(LVOT) and the aortic root. A collagenous aortic valve ring provides structural support to 
the aortic valve complex. The annulus is shaped like a crown and extends to the level of the 
aortic sinuses. The ring itself is further supported by its attachment to the vascular media 
distally and to the ventricular septum proximally and anteriorly.33
Thus, the aortic valve is normally tricuspid, with three semilunar leaflets. The 
aortic sinuses of Valsalva are small dilatations located just distal to the valve line, with a 
sinus corresponding to each leaflet (Figure 3). Each of the sinuses (and leaflets) is named 
after the corresponding coronary artery as the right, left and non-coronary sinuses (and 
leaflets). Normally, the left and right coronary arteries originate from the left and right 
aortic sinuses (in 91% and 93% of cases).34
Figure 3.
A, Echocardiographic, bioengineering 
and haemodynamic force perspectives 
of the diastole and systole in the aortic 
root affecting aortic valve leaflet cell 
and function.
B, Demonstration of the cellular 
architecture of a normal aortic valve. 
Reprinted with permission from 
Rajamannan et al., Circulation 2011.30
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At the centre of the free edge of each leaflet, there is a small fibrous bulge, named 
the nodule of Arantius. The rim (known as the ‘lunula’) of the free edge of each valve 
leaflet is slightly thicker than the body of the leaflet itself.. These lunulae of the different 
valve leaflets overlap at the time of valve closure in diastole to help seal the valve closure,
in addition they provide leaflet support. The leaflet’s rim can have fenestrations/holes, 
mostly located next to the commissures; however, these fenestrations have no known 
clinical significance.34
The leaflets of the valve have two distinctive surfaces, a ventricular surface and a 
vascular surface, each of which is exposed to different stress factors. During systole, blood 
flows with high velocity and opens the valve, whereas during diastole, the backward 
pressure of the blood fills the sinuses and closes the valve.35
1.3 CALCIFIC AORTIC VALVE DISEASE
Aortic valve sclerosis is the initial stage of progressive calcific aortic valve disease, 
especially calcific aortic valve stenosis (AS), which is the most common valvular heart 
disease in the Western world and accounts for most of the aortic valve replacements (see 
Table 1). Its number has doubled in the United States in the last 10 years, and figures are still 
on the rise.36 Echocardiographic evidence of aortic valve sclerosis, with or without stenosis, 
can be found in around one-fifth of the population between 65-75 years of age 37, 38 and in 
around half of the population older than 80 years. 38, 39 In a post-mortem series of 72 patients 
published in 1951, 22 patients had aortic valve calcification (AVC) and 38 had coronary 
calcification.40 The authors concluded that the higher age observed in AVC cases indicated 
that degeneration by age is an important factor in this condition. However, they pointed out 
that rheumatic infection was considered during the 1940s as a predominant reason for AVC, 
and that Mönckeberg suggested as early as 1904 that AVC had an atherosclerotic nature. 
Although aortic valve sclerosis and AVC were previously considered as degenerative 
phenomena and as natural consequences of aging, up to 50% of individuals older than 80 
years have no echocardiographic evidence of AVC.39
Despite that not all studies find a relationship between AVC and lipids, smoking or 
diabetes,39 several have found risk factors for AVC that were similar to those observed for 
atherosclerosis, such as old age, male sex, hypertension, elevated lipoprotein levels, smoking 
and type 2 diabetes mellitus.38, 41-43 AVC seems to be not only part of generalized 
atherosclerosis,44 but also a complex phenomenon that is related to other non-infectious and 
non-inflammatory processes.45, 46 The process of AVC is even related to bone formation in 
human embryos.47-49 Cell-mediated processes may influence calcium deposition, which is 
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more extensive and has an earlier onset in AVC compared with atherosclerosis.43, 50 A
spectrum of cell types is involved in the process of valvular calcium deposition, including not 
only valvular endothelial and interstitial cells, but also cardiac chondrocytes and circulating 
osteoprogenitor cells.35, 51 AVC is composed of calcium phosphate, mainly carbapatite, in 
both BAV and TAV, irrespective of concomitant coronary disease. 52 Genetics play a role in 
the pathophysiology of AVC, as exemplified by BAV, which is considered a risk factor for 
the early onset and progression of AVC.17, 53
Calcific aortic valve disease progresses slowly through a series of different stages, 
from valve thickening to calcification with or without impaired leaflet function. AVC may 
lead to restricted leaflet opening, i.e., aortic stenosis and/or inadequate leaflet closure, as 
observed in aortic regurgitation (AR). Some terms that describe the stages of sclerotic aortic 
valve disease are defined in Table 1. A summary of the risk factors for AVC was presented 
by Mohler; they include dyslipidaemia, hypertension, diabetes mellitus, smoking, bicuspid 
valve, hyperparathyroidism, end-stage renal disease and Paget’s disease.54
Table 1. Definitions of aortic valve sclerosis,55 aortic valve calcification and aortic valve stenosis.56
Aortic valve sclerosis Echocardiographically defined as focal areas of increased 
echogenicity and thickening of aortic valve leaflets with no evidence 
of aortic stenosis (Vmax < 2 - 2.5 m/s). 
Aortic valve calcification 
(AVC)
Defined as calcium deposition on aortic valve leaflets, as tiny spots or 
up to extensive calcification greatly affecting the mobility of the valve 
leaflets. On echocardiographic images, it presents as high echogenic 
(white) spots found on the valve leaflets. 
Aortic valve stenosis (AS) Subcategorized, according to the AHA/ACC 2014 guidelines, into 
stage A (patients at risk of AS), stage B (progressive AS with Vmax =
2–4 m/s) and stages C and D (severe AS with Vmax > 4 m/s; stage D 
patients are also symptomatic). 
1.3.1 Atherosclerosis and aortic valve calcification
Atherosclerosis is a disease of elastic and large muscular arteries, in which atheroma 
is the characteristic lesion. In the process of atherosclerosis, the arterial intima is enlarged by 
the deposition of variable amounts and types of lipids, connective tissue, inflammatory cells 
and extra-cellular components, including proteins, enzymes and calcium deposits.57-59
Atherosclerosis is the number one killer in the industrialized world. Extensive studies have 
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contributed to great progress in understanding its pathogenesis, risk factors, natural history, 
treatment and prevention.60
Thus, the development of aortic valve thickening and calcification is complex, and 
clearly related to,44, 61 but not fully explained by, atherosclerosis, rather than a simple wear 
and tear aging process.41, 43 As mentioned above, clinical studies that showed a significant 
association between risk factors of atherosclerosis and AVC support the hypothesis of its 
atherosclerotic nature.62, 63 Pathological studies have also proven that certain similarities exist
between vascular atherosclerosis and AVC.43, 64, 65 AVC and atherosclerosis seem to have 
common initiating events.66, 67 Nitric oxide release by the valvular endothelium is crucial 
for the maintenance of normal aortic valve elasticity.68 The renin–angiotensin system also 
contributes to the development of AVC, as angiotensin II, which is known to be involved in 
atherosclerosis development, was identified in diseased valves together with the 
angiotensin-converting enzyme (ACE), but not in normal aortic valve leaflets.69 The 
atherosclerotic process seems to continue even in advanced AVC, with accumulation of 
inflammatory cells, complement activation and expression of metalloproteinases.70-73 An 
ongoing active process characterized by the presence of neovascularization,74, 75 deposition 
of calcium76, 77 and lipid accumulation67, 75, 78 further proves the contribution of 
atherosclerosis to AVC development (Figure 4). 
Figure 4. Disease progression in calcific aortic stenosis showing changes in aortic valve histologic 
features, leaflet opening in systole. Reproduced with permission from The New England Journal of 
Medicine 2008, Copyright Massachusetts Medical Society.48
11
1.3.2 Biomarkers and aortic valve calcification
Several biomarkers of AVC have been addressed in the literature. The presence of 
AVC was associated inversely with platelet nitric oxide, which is an intrinsic vasodilator, 
and its responsiveness, which is a marker of endothelial dysfunction.79 An elevated blood 
level of cholesterol is a well-known risk factor for atherosclerosis.80 Studies aiming to 
associate AVC with blood lipids reported mixed results, as some proved the association 
between AVC and hypercholesterolaemia 38, 81-83 and elevated levels of lipoprotein(a);84
conversely, other studies failed to show this correlation.85-87 Inflammatory markers such as 
C-reactive protein levels seem to be more closely associated with AS than with measures of 
AVC.88, 89 However, C-reactive protein is related to AVC and is a prognostic marker of 
AVC,90, 91 with mixed results of AVC being present without significant AS.45, 92 A small 
study confirmed the relationship between AVC and the levels of plasma osteopontin,93 a
glycophosphoprotein that is involved in regulating bone remodelling.94 Osteoprotegerin 
may counteract valve calcification, as shown in mice and humans,95, 96 and is a prognostic 
marker of AS.97
1.3.3 Clinical importance of aortic valve calcification
Echocardiography is the main technique that is used for the evaluation of valvular 
disease. Echocardiographically, aortic valve sclerosis is defined as focal thickening of aortic 
valve leaflets with areas of increased echogenicity (calcium deposition) without restriction of 
leaflet motion and an antegrade Doppler velocity across the aortic valve < 2–2.5 m/s55 (see 
Table 1).
Several studies showed that AVC has a strong predictive value for cardiovascular 
morbidity and mortality in the general population. In one study, AVC independently 
predicted coronary artery disease (CAD), to a greater extent than sex, hypertension, family 
history and hypercholesterolaemia.98 An association was found between AVC and a higher 
prevalence of left ventricular hypertrophy, ventricular arrhythmias, myocardial infarction and 
systolic heart failure in the general population.99 AVC is associated with cardiovascular 
events independent of Framingham risk factors, but does add to prediction in addition to 
Framingham risk factors and coronary artery calcification.100 In another sample from the 
general population, AVC predicted cardiovascular mortality beyond information on risk 
factors, including coronary calcification.101
AVC predicted poor outcome in severe asymptomatic AS patients,102 and even in 
patients with mild and moderate AS.103 AVC was associated with reduced-flow-mediated 
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dilatation of the brachial artery,104 and the AVC score was correlated with early 
atherosclerotic markers, such as carotid intima–media thickness (IMT) and dispensability.105
AVC was associated with increased incidence of stroke and cerebral emboli.106
In patients with renal disease, AVC seems to be clinically and prognostically 
important. The prevalence of valvular calcification (including mitral annular calcification and 
aortic calcification) is increased among patients with chronic kidney disease undergoing 
haemodialysis. 37, 107-109Although AVC is not directly associated with the degree of renal 
dysfunction,110 it is associated with carotid IMT in patients on haemodialysis.111 Further, 
AVC is a powerful predictor of cardiovascular morbidity and mortality in patients with long-
term haemodialysis,107, 112 and a predictor of restenosis of drug-eluting stents in patients with 
CAD and chronic haemodialysis.113  
1.3.4 Management of calcific aortic valve disease
No specific treatment is currently available to prevent or reduce the rate of 
progression of the calcification of aortic valves. The involvement of cholesterol and other 
lipoproteins in the pathogenesis of AVC and AS found in experimental and clinical studies 
motivated the performance of lipid-lowering studies.114 An excellent review of lipid 
lowering in AS summarized five retrospective studies and one prospective non-randomized 
study, which were positive, and discussed in detail two randomized studies (SALTIRE, n = 
155; and SEAS n = 1873), with neutral results.115 Another randomized study, the 
ASTRONOMER trial, showed that lowering LDL-cholesterol blood levels did not stop the 
progression of AS or AVC in patients with mild-to-moderate aortic valve disease.116 Based 
on the involvement of the renin–angiotensin system in the development of AVC, it was 
hypothesized that the use of ACE inhibitors may halt or lead to the regression of calcium 
accumulation within aortic valve leaflets.117 Ongoing controlled randomized trials including 
ACE inhibitors, statins and biphosphonates are addressing this issue; however, to date, 
there is no conclusive evidence that medical therapy slows the progression of AS.118 Thus, 
although guidance for the medical prevention of calcific AS progression may be obtained 
within the next few years, the current treatment strategies deal with the haemodynamic 
consequences of severe AVC, including aortic valve stenosis and regurgitation. 
1.3.4.1 Diagnosis and management of aortic stenosis 
Based on the 2014 American College of Cardiology (ACC)/American Heart 
Association (AHA) Guideline for the Management of Patients with Valvular Heart Disease, 
a new approach has been adopted, not only regarding the way of writing and presenting 
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evidence, but also in describing the disease stage and management of patients with AS. A 
new grading system has been introduced based not only on the presence of symptoms and 
haemodynamic data, but also taking into account valve anatomy and calcium deposition, 
ranging from stage A (patients at risk of developing AS) reaching up to stage D (patients 
with severe symptomatic disease).56, 119 These stages constitute an important basis for 
treatment strategies and recommendations, and support the recommendations of the Joint 
Task Force on the Management of Valvular Heart Disease of the European Society of 
Cardiology (ESC) and the Guidelines on the management of valvular heart disease of the 
European Association for Cardio-Thoracic Surgery (EACTS).56, 119, 120
Based on different levels of evidence, treatment and procedure recommendations 
mentioned in guidelines are classified into: class I (recommended treatment/procedure),
class IIa (reasonably used), class IIb (might be used) and class III (may cause harm).
According to the 2014 AHA/ACC Guideline,56 medical therapy is mainly directed towards 
treating hypertension in all patients at risk of developing AS and in patients with AS stages 
B and C (Class I). Aortic valve replacement (AVR), either surgical or transcatheter aortic 
valve replacement (TAVR), is recommended for all patients with severe symptomatic AS 
(Class I). Patients with severe asymptomatic AS with left ventricular (LV) dysfunction or 
who are undergoing cardiac surgery for other indications are also recommended for aortic 
valve intervention (Class I). Aortic valve replacement is reasonable in patients with severe 
asymptomatic AS, patients with symptomatic low-flow/low-gradient severe AS with LV 
dysfunction (or normal LV function with severely reduced leaflet motion due to AVC) or 
patients with moderate AS undergoing cardiac surgery for other indications (Class IIa). 
Surgical aortic valve replacement (AVR) is recommended in all patients who are 
indicated for AVR with low or moderate surgical risk (Class I). When surgical risk is high 
and the expected post-TAVR survival is longer than 12 months (as evaluated by a team 
including cardiologists, cardiac surgeons and cardiac imaging and anaesthesia professionals 
with good expertise in valvular heart disease), TAVR is indicated (Class I). In the absence 
of the professional team and uncertain 12-month survival after intervention, TAVR is a 
reasonable (Class IIa) indication.56
1.3.4.2 Diagnosis and management of aortic regurgitation (AR) 
According to the 2014 AHA/ACC Guideline, AR is categorized into four stages, 
from stage A (patients at risk of developing AR), through to stages B and C and reaching 
stage D, which includes patients with severe symptomatic AR. The management of AR 
follows the stage of the disease and is further divided into medical therapy and intervention. 
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Medical therapy of AR is directed mainly towards lowering blood pressure (systolic > 140 
mm Hg) using calcium-channel blockers (dihydropyridine), ACE inhibitors or angiotensin 
receptor blockers, and is recommended for all patients with chronic AR and hypertension 
(Class I). ACE inhibitors/angiotensin receptor blockers and beta-blockers are the drugs of 
choice (Class IIa) for patients with severe AR in addition to LV dysfunction and/or 
symptoms who are not fit for surgery. Intervention (AVR) is indicated for all patients with 
severe symptomatic AR, regardless of LV function, patients with severe asymptomatic AR 
with LV dysfunction and patients with severe AR undergoing cardiac surgery for other 
indications (Class I). Furthermore, AVR is recommended for patients with severe AR and 
dilated LV dimensions with no symptoms or LV dysfunction (Class IIa). Patients with 
moderate AR can have AVR while undergoing surgery of the ascending aorta, mitral valve 
or coronary artery by-pass graft (Class IIa).56
1.3.4.3 Management of bicuspid aortic valve 
Thus, BAV is a congenital disease of the aortic valve, which is often associated 
with aortopathy with development of ascending aortic aneurysm and sometimes dissection. 
Its presence heralds complications that occur a decade earlier in life compared with TAV, 
such as AS, AR, infective endocarditis and thrombus formation.121 Treatment of BAV can 
be divided into either treatment of the aortic valve diseases that developed or treatment 
directed at the control or treatment of the accompanying aortopathy. Currently, no drug 
therapies have been shown to reduce the rate of progression of aortic dilation in patients 
with BAV. Medical treatment is merited in patients with BAV and hypertension in whom 
the control of blood pressure can reduce further stress on the aortic wall.56 Recommended 
therapies focusing on the aortopathy that is often associated with BAV include beta-
blockers, ACE inhibitors, angiotensin receptor blockers and adrenergic receptor 
antagonists.122, 123 Statins do not have any effect on mortality in patients with thoracic aortic 
aneurysm, despite the fact that they reduce it in patients with abdominal aortic aneurysm.124
Despite the theoretical advantages of beta-blockers and angiotensin receptor blockers in 
reducing the progression of thoracic aortic aneurysm disease, no randomized clinical study 
has proven their beneficial effects.56
1.3.5 Imaging of aortic valve calcification
Several diagnostic modalities have been used for the assessment of AVC and its 
complications in clinical practice and in research. CT scanning and TTE are the most 
frequently used imaging techniques.
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1.3.5.1 Role of echocardiography 
Transthoracic echocardiography (TTE) is currently the most frequently used tool for 
aortic valve assessment, including morphology, the presence of AR, LV function, aortic 
pathology and concomitant abnormalities of other valves.125 TTE is useful in identifying 
aortic valve morphology and type, although in the case of severely calcified valves, 
distinguishing BAV from TAV may be difficult.35 TTE is well suited to determine the degree 
of stenosis and whether an increased velocity is caused by valvular or by sub- or supra-
valvular stenosis. In cases with AR, TTE is useful in identifying the magnitude and cause of 
the regurgitation. In some cases, transoesophageal echocardiography (TOE) may be needed 
to assess aortic valve morphology, valvular dimensions prior to procedures, valvular and 
para-valvular lesions in addition to suspected complications, such as infective endocarditis.125
The guidelines for aortic valve assessment include the measurement of jet velocity 
and mean pressure gradient and the application of the continuity equation to calculate valve 
area. These measurements are exposed to several possible errors, because of variable 
measurement experience, the haemodynamic situation, machine settings and measurement 
standardization.48 The assessment of the aortic valve by echocardiography should comprise 
several echo windows and views. These include parasternal long axis and zoom for 
measurement of the LVOT, the aortic sinus, dimensions at the sinotubular junction (STJ) and 
ascending aorta and short axis view of the aortic leaflets (Figure 5), as well as an apical long 
axis view of the aortic leaflets and an apical 5-chamber view of the aortic leaflets. The 
different view should include colour Doppler, and the 5-chamber view should include pulsed-
wave and continuous-wave Doppler. In addition, suprasternal and right parasternal views 
may be required to assess maximum aortic flow velocity.
Figure 5.
Transthoracic echocardiography 
(TTE) short axis view at the 
level of the aortic valve showing 
a fully closed normal tricuspid 
aortic valve. LA, left atrium; 
RA, right atrium; RVOT, right 
ventricular outflow tract; NCC, 
non-coronary cusp; RCC, right 
coronary cusp; LCC, left 
coronary cusp. From our local 
TTE image archive.
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1.3.5.2 Role of computed tomography 
Echocardiography excels in haemodynamic measurements and for following up the 
development of AVC, especially at a late stage when it has developed to AS and/or AR. At 
an early stage, before haemodynamic alterations occur, CT can detect morphological changes 
and calcium depositions. The superior spatial resolution of CT enables it to provide the most 
accurate images and data regarding aortic valve anatomy and calcium content. CT calcium-
scoring capabilities were developed especially for the quantification of coronary calcium 
content, and the presence of the aortic valve in the same plane facilitated the use of these 
capabilities to quantify AVC.
For the quantification of calcium using CT machines, the scanner detects calcium 
deposits and displays them as bright spots or areas in the image. AVC is then quantified using 
the method originally introduced by Agatston. The method can be summarized as follows: 
each attenuation of 130 Hounsfield units or above with an area t3 pixels is considered a 
calcium deposit. The Agatston calcium score is then calculated by multiplying the measured 
area by an attenuation coefficient that depends on the maximum attenuation value in the 
region of interest and is expressed in Agatston units.126 Other measurements can be 
performed using CT, including 3-dimensional volumetric measurement127 and mineral mass 
measurement. The latter measurement was used in several studies because of its high
accuracy and reproducibility.128-132 The introduction of multi-slice computed tomography 
(MSCT) improved image quality and provided shorter rotation times and thinner slices.133
Currently, MSCT scanners are the most commonly used because of their lower radiation dose 
and lower cost.134, 135
CT provides the only non-invasive method of quantification of AVC. AVC CT 
scoring has gained additional importance recently with the increasing implementation of 
TAVR procedures, because of its high precision in detecting the position and amount of 
AVC, in addition to aortic valve dimensions, which are crucial for the selection of proper 
valve size.136
1.3.5.3 Other in vivo techniques 
Because of its advantages of avoiding radiation exposure and providing good image 
quality, magnetic resonance imaging (MRI) has been used to assess the geometry of the 
aortic valve, determine effective and geometrical orifice areas and perform haemodynamic 
measurements. These measurements are particularly useful at a later stage of the AVC 
process, at which significant valve lesions have developed. Because of its inability to 
RVOT
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diagnose calcification, its lower spatial resolution compared with CT and its higher cost, MRI 
cannot be used to assess AVC in its earlier stages.125 It is worth mentioning here the presence 
of some efforts aimed at quantifying calcification in tissues using MRI ultra-short echo time 
imaging,137 although without notable success to date.
A recent study showed good results for the evaluation of AVC and aortic valve 
inflammation using positron emission tomography (PET) in patients with AS, in whom the 
increased activity of the tracer used correlated with disease severity.138
Similar to MRI, cardiac catheterization is of value at the later stage of the disease, 
because of its superiority in providing reliable haemodynamic measurements. Despite the 
increasing use of cardiac catheterization in the past few years because of the increase in the 
use of TAVR procedures, its application is confined to later stages of AVC, for assessing
haemodynamic valvular disorders; however, it is not as useful in the early stages of the 
disease because of its weakness in identifying and quantifying calcification.56, 125
1.3.5.4 Ex vivo computed tomography 
Ex vivo CT scanning of different body tissue specimens to quantify calcium content 
is a growing field of research. It has been used to quantify calcium in carotid specimens139
and in excised aortic artery leaflets.133 Ex vivo CT AVC scoring is an appealing field of 
research, as it does not encounter some of the difficulties inherent to in vivo scanning, such as 
coronary ostial calcification, motion artifacts and calcification overestimation in contrast 
examinations.140 In a single study using electron beam CT (EBCT), a good correlation was 
found between in vivo and ex vivo AVC.140 In a micro CT study, AVC volume correlated 
well with AS severity.141 Inter-scanner variability was further reduced and image quality 
improved after the introduction of MSCT, as it provided shorter rotation times and thinner 
slices.133 The calcium-scoring accuracy and reproducibility of CT scanners were also 
improved by the introduction of new measurement units and calculation methods, such as 
mineral mass (MM) and calibration phantoms using calcium hydroxyapatite (CaHA).129-133
Despite all these efforts in the field, there is currently no scanning and reconstruction protocol 
that is widely used or agreed upon, as the detection threshold, calibration factor, slice 
thicknesses and reconstruction protocols vary between different studies, which renders 
comparison tricky and not very reliable.
18
19
2 AIMS
The overall aim of the thesis was to evaluate imaging methods in vivo and ex vivo to 
estimate aortic valve calcification. The specific aims were as follows.
1. To investigate the accuracy of AVC estimation using a 5-degree visual scoring 
system on echocardiographic images (Studies I and II). 
2. To compare TTE and TOE for AVC scoring (Study II).
3. To assess the value of GSM for the quantification of AVC (Studies I and II). 
4. To develop a protocol for ex vivo CT calcium scoring (Study III). 
5. To compare in vivo echocardiography to ex vivo AVC evaluation (Study IV). 
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3 METHODS
3.1 PATIENTS
The patients included in these studies were recruited from a large prospective study 
(Advanced Study of Aortic Pathology (ASAP)) that included 600 patients undergoing cardiac 
surgery because of aortic valve lesions and/or aortic root or ascending aortic pathology. 
ASAP is a unicentre study conducted at the Karolinska University Hospital, Stockholm. All 
patients underwent open-heart surgery at the Department of Thoracic Surgery, ultrasound 
investigations were performed at the Department of Clinical Physiology and blood tests were 
performed at the Department of Clinical Chemistry.
The exclusion criteria of the ASAP study were age <18 years, inability to give an 
informed consent or patient refusal to take part in the study, significant CAD, blood-borne 
infections, prior cardiac surgery and indication for other concomitant valve surgery.
The patients who were enrolled in the study were evaluated preoperatively by 
questionnaire regarding medical history, cardiovascular risk profile, concomitant diseases and 
medications, further laboratory tests, echocardiography and diagnostic coronary angiography. 
Intra-operatively, the surgeon determined the type of aortic valve by direct inspection 
(number of leaflets and commissures), in addition to scoring visually the calcification of the 
valve via the AVC scoring system used in the study (Table 2).
In this thesis, we performed four different studies. The first two studies (Studies I 
and II) included 185 and 169 patients; all patients included in Study II were part of Study I,
and both studies included patients from the first 207 patients enrolled in ASAP. The first two 
studies concentrated on assessing AVC using echocardiography and testing a greyscale 
(GSM) computer software against visual scoring using the intra-operative score (IOS) as a 
gold standard. Study III was methodological in nature and did not include any patients. This 
study aimed at identifying the most suitable conditions for ex vivo CT scanning of small 
tissues for calcium scoring. In Study IV, 155 patients were included from among the later 300 
patients of the ASAP (none of whom were included in the previous studies). In this study, we 
applied the results obtained in Study III for ex vivo CT scanning of the surgically excised 
aortic valves.
22
3.2 ECHOCARDIOGRAPHY
3.2.1 Transthoracic echocardiography
All patients underwent comprehensive TTE using a Philips IE33 ultrasound scanner 
with an S5-1 transducer (1–5 MHz) (Philips Healthcare, Best, the Netherlands). Aortic valve 
morphology and function were assessed by an experienced echocardiographer. Studies were 
performed within 1 week of surgery, and all images were stored digitally for offline analysis
(Figure 6).
3.2.2 Transoesophageal echocardiography
A comprehensive TOE study was performed in the operating room immediately 
before the heart surgery using a Sequoia c512 ultrasound scanner (Siemens Medical Systems, 
Mountain View, CA, USA) with a V5Ms TOE transducer at a frequency of 6 or 7 MHz. All 
TOE studies were performed by experienced investigators, with focus on the aortic valve and
aortic root morphology and function. Ultrasound images were digitally stored and analysed 
offline on dedicated work stations (Figure 6).
Figure 6. Sample valves from the study showing explanted valves, transthoracic and transoesophageal
echocardiographic images (left to right). Top, mildly thickened tricuspid aortic valve. Bottom,
heavily calcified bicuspid aortic valve.
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3.3 AORTIC VALVE CALCIFICATION SCORING SYSTEM 
A 5-grade AVC scoring system was used, starting at grade 1 (normal aortic valve 
leaflet(s)) and up to grade 5 (heavily calcified aortic valve leaflet(s)). Description of the five 
grades is summarized in Table 2. 
Table 2. Aortic valve calcification scoring system.
Grade Description
1 Normal leaflets with no evidence of thickening or calcification
2 Evidence of thickening (sclerosis), but no evidence of calcification
3 Calcification (small calcium spot(s) not exceeding one-third of the leaflet area)
4 Moderate calcification (calcification not exceeding two-thirds of the leaflet area)
5 Heavily calcified (calcification covering more than two-thirds of the leaflet area)
The scoring system was used in all visual assessments of echocardiography images, 
both TTE and TOE, image examples shown in Figure 6. Scoring was performed using real-
time images from the short axis view at the level of the aortic valve at the base of the heart, 
where each leaflet was given a single score and the average of the valve AVC score was 
calculated. All AVC scoring was performed by two experienced echocardiographers (MY 
and AR) at different occasions. These individuals were unaware of the other’s results. This 
applies to real-time and still image evaluation using either TTE or TOE images.
A still frame of the aortic valve in the parasternal short axis view at the end-diastolic 
phase with fully closed aortic valve leaflets was used to score AVC by assigning a single 
score to the whole valve.
3.4 GREYSCALE MEASUREMENT SOFTWARE
For the computerized evaluation of ultrasound reflection from the aortic valve, a 
software that was developed for atherosclerotic plaque analysis (Artery Measurement 
System, AMS-II) was used. It was developed by collaborative work between the Physiology 
Group at the Wallenberg Laboratory (www.wlab.gu.se), Gothenburg University, Sweden and 
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the Department of Signals and Systems at Chalmers University of Technology, Gothenburg 
to quantify intima–media thickness (IMT) and for greyscale evaluation of carotid plaque.142
A parasternal short axis view still frame with the aortic valve leaflets fully closed at 
end-diastole was used for AVC quantification using the AMS II (GSM) software 
(investigator MY), Figure 7. For each patient, a greyscale calibration was performed using a 
sample of the intravascular blood pool (avoiding areas of noise) as the black reference 
(greyscale value of 0), and the brightest part of the pericardium (or occasionally a calcium 
spot within the leaflets, if the pericardium was not visualized in the image used) as the white 
reference (greyscale value of 255).143 A region of interest was manually drawn around the 
aortic valve leaflets, excluding the annulus, and the greyscale mean (GSMn) of the valve was 
automatically calculated by the AMS program. We used GSMn rather than the median, as 
valvular calcification may be unevenly distributed.
Figure 7. Greyscale measurement software 
(AMS-II) results screen.
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3.5 INTRA-OPERATIVE SCORE
Intra-operative AVC scoring (IOS) was performed by the operating surgeon at the 
time of the operation via gross inspection and palpation of the aortic valve leaflets (Studies I, 
II and IV). The surgeon gave a single score for the whole aortic valve using the same 5-
degree scoring system as that used for AVC scoring on echocardiographic images.
3.6 EX VIVO COMPUTED TOMOGRAPHY
Computed tomography was performed using a Siemens Symbia T16 True Point 
hybrid single-photon emission computed tomography/computed tomography (SPECT-CT) 
(Siemens Medical Solutions USA, Inc., Knoxville, TN) scanner (Studies III and IV). Raw 
data were processed on the main CT work station and stored digitally for further analysis 
using different reconstruction parameters. Calcium scoring was performed using the default 
Siemens calcium-scoring module found as part of the Symbia analysis software using a 
Siemens work station. The default program settings for in vivo coronary calcium scoring 
were used in addition to other modified protocols. The calcium-scoring program was used to
detect calcification by applying the default or the pre-specified parameters. The detected 
calcifications were given a magenta colour by default, and were then manually selected by 
the user to score the calcium found in the selected area. The software provided calcium 
scoring in volume (mm3), MM (mg CaHA) and calcium score. See Table 3 for definitions.
Table 3. Definitions of factors used in calcium scoring by computed tomography (CT).
Calibration factor A reconstruction factor used by the CT calcium-scoring work station 
assuming the calcium density in a lesion/phantom. Measured in mg 
CaHA/cm3.
Threshold value
A reconstruction factor used by the CT calcium-scoring work station 
to assign the lower threshold for the detection of calcium presence in a 
lesion/phantom. Measured in HU. 
Slice thickness A scanning and/or reconstruction parameter used by a CT scanner 
denoting the number of images taken/reconstructed per mm. Measured 
in number of images/mm 
Mineral mass (MM)
A calcium measurement value used by the CT calcium-scoring work 
station to detect the amount of calcium found in a lesion/phantom. 
Measured in mg CaHA.
CaHA, calcium hydroxyapatite; HU, Hounsfild Units.
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3.6.1 Computed tomography scanning of phantoms
In our methodological study (Study III), different types of phantoms containing CaHA at 
different concentrations in different types of surrounding media were used. Therefore, we 
used different CT scanning and reconstruction parameters to identify the most suitable 
conditions for ex vivo tissue CT scanning and calcium scoring. The commercially available 
Cardiac CT Calibration Insert Phantom for the Quantification of Coronary Calcium (QRM, 
Möhrendorf, Germany) contained nine cylindrical CaHA inserts with different size, density 
and mass, plus two large calibration inserts made of a water-equivalent material and 200 
mg/cm3 CaHA (QRM Phantom product manual; http://www.qrm.de/content/pdf/QRM-Cardio-
Phantom.pdf) (Figure 8).
             
Figure 8. Cardiac CT Calibration Insert Phantom for the Quantification of Coronary Calcium (QRM, 
Möhrendorf, Germany).
Further, we used a series of “in-house-produced” test-tubes containing different 
concentrations of CaHA (50, 150, 250, 500, 1000, 1500 and 2000 mg CaHA) immersed in 
different types of surrounding media (air, 0.9% saline and 70% ethanol), Figure 9. We used 
4.5 u 1 cm plastic tubes with a screw plastic cap. Scanning was always performed in the 
median plane of the scanner. We also put the tubes in a larger container that had the same 
type of surrounding media as the small tube, to test the effect of increasing the amount of 
surrounding media on the results obtained.
Figure 9. “In-house-produced” test-
tube phantoms containing known 
masses of calcium hydroxyapatite 
(CaHA).
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3.6.2 Computed tomography of explanted aortic valve leaflets
In Study IV, all valves that were explanted during open-heart surgery were 
immediately stored either in RNA-later (ribonucleic acid stabilization and storage reagent 
solution) or in formaldehyde solution for 24 h, followed by ethanol treatment, until analysis. 
Each valve was scanned in a plastic culture dish immersed in normal saline solution (sodium 
chloride, 0.9%). Before CT scanning, the valve fragments were dried from the medium, 
carefully put in the plastic dish and then introduced into the CT machine. The actual scanning 
was performed at a slice thickness of 0.6 mm, and reconstruction of the offline-saved raw 
data file was done using the B50 reconstruction protocol, 0.75 mm slice thickness, a threshold 
level of 130 HU and a calibration factor of 0.600 mg CaHA/cm3, which were the settings that 
proved to be most reliable and reproducible, as described in our phantom investigation (Study 
III). For the offline analysis of calcium content, we used the Siemens CT work station 
calcium-scoring software, as described previously. The CaHA equivalent MM of each valve 
was then calculated and used for later comparisons.
3.7 EX VIVO VALVE WEIGHT
The weight of each valve was obtained using a Sartorius Extend ED153-CW scale 
(Sartorius AG, Göttingen, Germany) with a sensitivity of 0.001 grams. The scale was 
calibrated with an atmosphere seal. Prior to weighing, all valve fragments were carefully 
dried from any excess medium using soft study tissue. The total valve weight was recorded. 
The valve was then returned to the tube together with the medium for later studies.
3.8 LABORATORY INVESTIGATIONS
All blood samples were obtained in the fasting state and were analysed for plasma 
concentrations of creatinine, high-sensitivity C-reactive protein (hsCRP) RP, high-density 
lipoprotein (HDL), low-density lipoprotein (LDL) and serum concentrations of cholesterol 
and triglycerides at the Laboratory of Clinical Chemistry at Karolinska University Hospital 
using standard methods (Unicel DXC 800 Synchron, Beckman Coulter, Brea, CA, USA).
3.9 STATISTICAL ANALYSIS
For all statistical analyses, IBM SPSS (Statistics Chicago, IL, USA) was used. We 
used the latest versions of the program that were available at the time of the study (versions 
17.0.2 and 22.0). Descriptive statistics and frequencies, mean values and standard deviations 
are presented for normally distributed data. Pearson’s product moment correlation coefficient 
(r) was computed to evaluate the relationship between two variables. We used Wilcoxon’s 
test for paired samples, and the Mann–Whitney U test for unpaired samples in Study I. 
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Student’s t test and the chi-squared test were used as applicable to compare means and 
determine significant differences between variables and characteristics in Studies II and IV. 
Inter- and intra-observer variability were analysed using the intra-class correlation coefficient 
(ICC), with values above 0.75 representing good correlation and values between 0.4 and 0.75 
indicating fair reproducibility. A linear regression analysis was used to create the regression 
formula used to predict valve weight using CT MM measurement. Coefficients of variation
(CV) were computed to illustrate reproducibility in Study III. A p-value of < 0.05 was 
considered significant in all studies of the thesis.
3.10 ETHICAL CONSIDERATIONS
The Regional Ethics Review Board at Karolinska Institutet, Stockholm, Sweden 
approved the study protocol and all patients gave their informed consent to participate.
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4 RESULTS
4.1 IN VIVO ASSESSMENT OF AORTIC VALVE CALCIFICATION (STUDIES I, II 
AND IV)
As echocardiography is the dominant method for evaluation of cardiac valves, a 
major goal was to determine the possibility to estimate AVC by this technique, using both 
TTE and TOE approaches. We compared the different methods to interpret the 
echocardiographic recordings with an intra-operative 5-degree score (Table 2) of a similar 
construction (Studies I and II), and to valve weight and ex vivo CT (Study IV).
In Study I, we used the TTE investigations from 185 patients (104 with BAV) to 
compare visual AVC scoring and greyscale assessment with the surgeons intra-operative 
score (IOS). In Study II, in all patients of Study I who had an available TOE investigation (n 
= 169), we evaluated if a higher resolution or better image with TOE would increase the 
diagnostic accuracy compared with the IOS. Finally, in Study IV, we evaluated, in 155 
patients, the accuracy of the echocardiographic evaluations of AVC, as well as the intra-
operative scoring against the actual weight of the valve, and the CT scoring. The relation 
between the latter two was also analysed.
Baseline characteristics and echocardiographic measurements of the 185 patients 
and subgroups studied here are summarized in Tables 4 and 5. The demographic data used in 
Study II did not differ from that of Study I. Thus, for Studies I and II, the average age was 
63.9 ± 11.6 and 63.7 ± 11.6 years, and the proportion of females was 31% and 30.2%, 
respectively. A higher percentage of dilated aortic roots (52%) was observed in the BAV 
group, up to 72% in patients with AR, compared with only 30% in the TAV group, and as 
low as 7% in TAV with AS.
The higher-age group of BAV and TAV (t 65years) included more females and 
more AS cases than did the younger-age group (< 65years). Lesion type, haemodynamics and 
GSMn according to subgroup are shown in Tables 4 and 5. For comparison between studies, 
some demographics used in the in vivo investigations (Studies I, II and IV) are shown in 
Table 6. 
The observer variation for AVC scoring (Table 2 and Figure 10) was low, with high 
correlations. In Study I, the inter- and intra-observer variability measured by ICC for real-
time TTE scoring were 0.93 and 0.93, respectively, whereas those for still frames were 0.90 
and 0.85, respectively. In Study II, where we explored whether TOE images would improve 
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the correlations to IOS, the ICC between two observers was 0.93 for real-time TTE and 0.94 
for TOE.
Table 4. Patient characteristics according to valve type (Study I).
AAD, aortic aneurysm or dissection; AS, aortic stenosis; AR, aortic regurgitation; BSA, body surface area; 
BAV, bicuspid aortic valve; TAV, tricuspid aortic valve. 
In group comparisons the ultrasound reflectivity, objectively measured in terms of 
the GSMn of end-diastolic still frames of the fully closed aortic valve, was higher in AS than 
in AR, for both BAV and TAV (Table 5). The GSMn evaluated in still frames was clearly 
higher in AS than in AR, and somewhat higher values for AS were obtained in TTE 
compared with TOE (Figure 11). The AVC difference between BAV and TAV was not more 
obvious in GSMn than in the visual scoring of still frames (Table 7). In contrast, both the IOS 
and real-time evaluation by both TTE and TOE showed highly significant differences 
between BAV and TAV. Furthermore, the overall score was numerically higher and 
essentially similar using IOS and real-time evaluation than using still frame interpretation, 
which yielded lower scores (Table 7 and Figure 12). The differences between BAV and TAV 
were essentially noted in the AR groups (Figure 12).
All patients 
(n = 185)
n (%)
BAV patients
(n = 104)
TAV patients
(n = 81)
< 65years
(n = 66)
n (%)
t 65years
(n = 38)
n (%)
< 65years
(n = 25)
n (%)
t 65years
(n = 56)
n (%)
Mean age (years) 63.9 ± 11.6 54.6 ± 8.9 72.1 ± 4.8 54.4 ± 8.2 73.6 ± 5.1
Females, n (%) 57 (31) 15 (23) 14 (37) 4 (16) 24 (43) 
Weight (kg) 82 ± 15 85 ± 14 77 ± 12 88 ± 11 80 ± 17
Height (cm) 175 ± 10 178 ± 9 173 ± 8 178 ± 9 171 ± 11
BSA (m2) 1.97 ± 0.2 2.03 ± 0.18 1.9 ± 0.17 2.06 ± 0.15 1.92 ± 0.23
AS, n (%) 109 (59) 34 (52) 34 (89) 4 (16) 37 (66)
AR, n (%) 61 (33) 24 (36) 1 (3) 20 (80) 16 (28)
AS/AR, n (%) 8 (4) 5 (8) 2 (5) 0 1 (2)
AAD, n (%) 7 (4) 3 (5) 1 (3) 1 (4) 2 (4)
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Table 5. Echocardiography data and study results according to aortic valve phenotype and primary 
lesion (Ascending aortic aneurysm and mixed lesion valves not shown) (Study I).
AR, aortic regurgitation; AS, aortic stenosis; ED, end-diastolic, ES, end-systolic, AVC, aortic valve calcification; 
LVOT, left ventricular outflow tract.
Figure 10. Transthoracic and transoesophageal short axis view images from our studies showing 
aortic valves representing the 5 grades used in our scoring system and their schematic drawings. 144
Variables
Bicuspid valve
(n = 93)
Tricuspid valve
(n = 77)
AS
(n = 68)
AR
(n = 25)
AS
(n = 41)
AR
(n = 36)
Aortic root, ED diameter 
(mm) 36.1 ± 5.8 42.0 ± 6.7 32.1 ± 4.3 42 ± 6.9
Ascending aorta, ED 
diameter (mm) 40.4 ± 7.6 44.6 ± 7.6 33.8 ± 4.6 43.4 ± 9.4
Ascending aorta, ED 
diameter > 40 mm, n (%) 29 (43) 18 (72) 3 (7) 18 (50)
LVOT, ES diameter (mm) 22.8 ± 2.8 27.4 ± 3.9 20.8 ± 1.8 24.4 ± 3.4
Aortic valve area (cm2) 0.9 ± 0.4 3.0 ± 1.0 0.8 ± 0.3 3.2 ± 1.1
Aortic valve peak gradient 
(mmHg) 80.1 ± 31.4 20.4 ± 14.4 77.6 ± 19.9 15.4 ± 8.0
Aortic valve mean gradient 
(mmHg) 51.1 ± 19.7 12.0 ± 8.7 48.9 ± 13.5 8.0 ± 3.9
Surgical AVC score 4.5 ± 0.7 2.5 ± 1.1 4.3 ± 0.9 1.4 ± 0.6
Greyscale mean 78.0 ± 18.2 44.2 ± 18.8 91.3 ± 22.1 34.8 ± 13.5
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Table 6. Comparison of age, sex, aortic diameter and aortic stenosis in the echocardiographic 
investigations (Studies I, II and IV) according to valve type.
AS, Aortic stenosis; AscAo, ascending aorta; BAV, bicuspid aortic valve; TAV, tricuspid aortic valve.
Figure 11. Greyscale mean (GSMn) in relation to the valve type and the aortic valve lesion. BAV, 
bicuspid aortic valve; TAV, tricuspid aortic valve; AS, aortic stenosis; AR, aortic regurgitation, TTE, 
transthoracic echocardiography; TOE, transoesophageal echocardiography.144
78.3 
71.5 
91.2 
78.0 
44.2 
49.0 
34.8 
47.4 
0
10
20
30
40
50
60
70
80
90
100
TTE Grey scale mean TOE Grey scale mean
G
SM
n 
BAV AS TAV AS BAV AR TAV AR
n Age(years)
Female
n (%)
AscAo
mm
AscAo
> 40 mm
n (%)
AS
n (%)
Study I 185 63.9 ± 11.6 57 (31) 40.7 ± 8.6 78 (42) 109 (59)
BAV 104 61.0 ± 11.4 29 (28) 42.1 ± 8.0 54 (52) 68 (65)
TAV 81 67.7 ± 10.8 28 (35) 38.8 ± 9.0 24 (30) 41 (50.6)
Study II 169 (all in Study I) 63.7 ± 11.6 51 (30) 40.9 ± 8.5 72 (43) 99 (58.6)
BAV 98 61.2 ± 11.7 27 (28) 42.1 ± 7.7 51 (52) 64 (65.3)
TAV 71 67.1 ± 10.8 24 (34) 39.2 ± 9.1 21 (30) 35 (49.3)
Study IV 155 (none in
Studies I or II)
64.6 ± 12.6 51 (33) 40.1 ± 8.0 71 (46) 107 (69)
BAV 81 58.9 ± 12.0 19 (23) 41.8 ± 7.4 46 (57) 52 (64)
TAV 74 74.7 ± 10.1 32 (43) 38.3 ± 8.2 25 (34) 55 (74)
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Table 7. Mean values of different AVC scoring methods, BAV vs TAV groups (Study II).
BAV, bicuspid aortic valve; TAV, tricuspid aortic valve; TTE, transthoracic echocardiography; TOE,
transoesophageal echocardiography, AVC, aortic valve calcification.
Figure 12. Mean aortic valve calcification (AVC) score according to valve lesion, valve type and type 
of evaluation (Study II). BAV, bicuspid aortic valve; TAV, tricuspid aortic valve; AS, aortic stenosis; 
AR, aortic regurgitation; TTE, transthoracic echocardiography; TOE, transoesophageal 
echocardiography; IOS, intra-operative score.144
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Figure 13. Pearson’s correlation coefficients for the comparison with intra-operative score using 
visual scoring of still frames and real-time loops (Study II). BAV, bicuspid aortic valve; TAV, 
tricuspid aortic valve; TTE, transthoracic echocardiography; TOE, transoesophageal 
echocardiography; IOS, intra-operative score.
In TTE images, the GSMn did not improve the correlation with the intra-operative evaluation 
(r = 0.73 vs. 0.72 for TAV and r = 0.56 vs. 0.57 for BAV; Table 4 in Paper I). The 
relationships between the ultrasonic evaluations and the IOS in Study II are shown in terms of 
correlation coefficients (Figure 13). It is obvious that GSMn did not for TTE, neither for 
TOE, provide better correlations to IOS than did the visual scoring of still frames.
Higher correlations with the intra-operative score were obtained when real-time 
evaluation of TTE was used (overall correlations to IOS for two independent observers r =
0.83 and r = 0.82; see Table 4 in Paper I). The correlations were somewhat higher for TAV (r
= 0.83 and 0.84) than for BAV (r = 0.78 and 0.76). Also in Study II scoring of real-time loops 
yielded the closest correlations with IOS overall: r = 0.83 for TTE and r = 0.82 for TOE. The 
real-time score correlations to IOS were somewhat higher numerically within the TAV group 
than within the BAV group, but less than for visual or GSMn evaluation of still frames 
(Figure 13). As seen in Figure 13, correlations to IOS were not higher for TOE than for TTE 
applying GSMn or visual AVC scoring.
Thus, the evaluation of both TTE (Study I) and TOE (Study II) by visual scoring and 
GSMn showed that real-time evaluation was superior to evaluation using still frames, both 
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via eyeballing or greyscale measurement. Therefore, we focused on real-time evaluation to
determine its accuracy in greater detail by applying both another cohort and another gold-
standard approach (Study IV). For demographic comparison, see Table 6. Compared with 
Studies I and II, the Study IV TAV group was somewhat older, with a slightly higher 
proportion of women compared with those in Study I. Within the cohort of Study IV, valve 
type groups (TAV 74 (48%) and BAV 81 (52%)) did not show significant differences 
regarding clinical data or laboratory results, with the exception of male predominance and 
lower age in BAV compared with TAV (Table 1 of Paper IV). In addition to the evaluation of 
real-time loops in the short axis, one leaflet at a time as described in Studies I-II, we added a 
composite visual evaluation of the aortic valve from different views in the TTE recordings. 
The intra-operative score was also compared with the gold standard used in Study IV, i.e., the 
mineral mass measured by ex vivo CT, and with valve weight. In addition to the comparison 
with the gold standards, we compared the estimation of AVC with aortic valve area and mean 
pressure; with hsCRP level, cholesterol, serum creatinine, body surface area and mass index; 
and with medical history of diabetes, hypertension, stroke and other diseases (Table 2 of 
Paper IV).
All estimations of AVC were related to aortic valve area and mean pressure, but 
none were significantly related to any of the other mentioned variables. Interestingly, the 
echocardiographic evaluations and IOS were related more closely to aortic valve area and 
mean gradient than were the mineral mass and valve weight. We also evaluated separately in 
the BAV and TAV groups the relationships between all measures of AVC and valve weight, 
aortic valve area and mean gradient, as well as hsCRP. There were significant relationships 
between all parameters, with the exception of hsCRP, and the strongest relationship observed 
was that between mineral mass and aortic valve weight in both BAV and TAV. There was no 
clear difference between the real-time methods of evaluation of AVC; importantly, TOE was 
not better than TTE. Moreover, in valve groups, the relationships with valve lesion measures 
were weaker for mineral mass and valve weight than they were for echocardiographic 
measures of AVC.
4.2 AORTIC VALVE PHENOTYPE (STUDY II)
An additional goal of Study II was to compare the accuracy of the diagnosis of aortic 
valve BAV phenotype by TTE and TOE using the intra-operative assessment as the gold 
standard. We used real-time images from both the TTE and TOE studies to determine aortic 
valve phenotype. The results (summarized in Table 8) showed that using TOE images 
enabled the investigator to diagnose the presence of BAV with a sensitivity of 92% and a 
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specificity of 94%; moreover, the inter-observer agreement between two independent 
investigators was excellent, as denoted by a kappa value of 0.86. Conversely, using TTE, 
BAV was recognized with a sensitivity of 77%, a specificity of 82% and a moderate Kappa 
agreement value of 0.57. When no or mildly calcified valves were considered separately, the 
specificity and agreement values for diagnosing BAV were slightly better compared with 
assessments performed considering more calcified valves, both for TTE and TOE. TOE was 
also superior to TTE in this group of patients.
Table 8. Bicuspid aortic valve diagnosis in relation to AVC degree; agreement with the surgical intra- 
operative assessment (Study II).
AVC, aortic valve calcification score; N, kappa value. Inter-observer agreement: N = 38% and 90% for 
transthoracic (TTE) and transoesophageal (TOE) echocardiography, respectively.
4.3 CALCIUM CONTENT—PHANTOM CT STUDIES OF SMALL OBJECTS
(STUDY III)
To use ex vivo CT as a gold standard for the evaluation of echocardiographic 
techniques, and to develop a useful protocol for ex vivo CT applications using small tissue 
materials, we performed this methodological study. As both the settings of equipment and 
surrounding media may influence the results, we evaluated various alternatives of both 
parameters. In addition to different settings, we used two types of phantoms. Each step was 
designed to test different values of a single parameter while keeping the other unchanged.
We found that the calcium scoring software of the CT work station (originally 
designed for scoring coronary calcium) was not able to quantify calcium masses of more than 
Compared with 
intra-operative 
assessment
True 
positive
True 
negative
False 
positive
False 
negative
Agreement 
(N value) Sensitivity Specificity
Mild or 
no AVC
(AVC 
score d 3)
TTE 18 30 5 7 0.58 72% 78%
TOE 22 34 1 3 0.86 88% 97%
Moderate 
to severe 
AVC
(AVC 
score > 3)
TTE 57 28 8 16 0.53 78% 78%
TOE 68 33 3 5 0.84 93% 92%
All valves
TTE 75 58 13 23 0.57 77% 82%
TOE 90 67 4 8 0.86 92% 94%
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2 g as a single mass when scanned in air. This was demonstrated when we used five test-
tubes containing 1, 2, 3, 4 and 5 g of CaHA in air, in which the software could detect all 
CaHA in all tubes, but failed to score masses beyond 2 g, as this value exceeded its maximum 
measuring capacity, as denoted by the software.
We then aimed at testing the effect of different media surrounding the CaHA mass 
to be scored. For this, we used two tubes containing 50 and 150 mg of CaHA per each 
medium to be studied. We tested several media, including air, normal saline, zinc 
formaldehyde, OCT (optimum cutting temperature imbedding medium), ethanol and RNA-
later. Within this step, we also tested two different calibration factors during offline scoring 
of CaHA, with the machine defaults at 0.772 mg CaHA/cm3 and 0.600 mg CaHA/cm3. 
Favourable results were obtained when using 0.600 mg CaHA/cm3 as a calibration 
factor and saline, which showed values of 51.4 and 149.9 mg for the 50 and 150 mg CaHA 
tubes. Good results were obtained when measuring the 50 and 150 mg CaHA tubes using 
zinc formaldehyde (54.9 and 158.8 mg), OCT (51.0 and 150.7 mg), followed by ethanol (39.8 
and 121.7 mg); less favourable results were obtained using air as the surrounding medium 
(19.5 and 68.7 mg, respectively). RNA-later as a surrounding medium was itself detected as 
calcium, showing the whole tube as a single calcium mass.
When the QRM phantom was evaluated using both 130 HU and 90 HU thresholds, 
while other parameters were kept fixed, we did not find any significant difference between 
the 130 HU and 90 HU thresholds regarding the measured values of the true CaHA masses 
(range, 72.1–96.3% and 72.6–96.9%, respectively). These results were obtained by 
measuring masses ranging between 4.2 and 78.5 mg CaHA inserts. Tiny inserts (0.2–0.6 mg 
CaHA) were either not detected or scored at a much lower percentage of their true values.
When the same experimental 130 HU and 90 HU thresholds were applied to the “in-
house-produced” phantom tubes containing 50 and 150 mg CaHA in either air or saline, 
similar results were obtained, with no significant differences.
In the next step, we compared slice thicknesses of 1 and 0.75 mm. We used the 0.75 
mm slice thickness as a default, which can be theoretically more accurate for small masses. 
However, no significant difference was noted when the results were compared with those 
obtained using a 1 mm slice thickness and a threshold of 130 HU. In contrast, the use of the 1 
mm slice thickness was marginally more accurate compared with 0.75 mm when the 90 HU 
threshold was used; this was only shown at larger insert masses (19.6 mg CaHA and above), 
and not at smaller masses.
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The effect of the surrounding medium was further tested using “in-house-produced” 
tubes containing known masses of CaHA inserted in air, saline or ethanol. Saline was 
superior to the other media as a surrounding medium for ex vivo scanning of tissues for 
calcium scoring (range, 83.8–103.9% of the true CaHA mass). Air was the least favourable 
medium, with the measured CaHA mass ranging between 31.6% and 45.2% of the true mass.
When evaluating the effect of the amount of the surrounding medium on the 
measurements, we found that saline was superior to air and ethanol. Larger amounts of the 
surrounding medium (in a container) resulted in lower measured values compared with lower 
amounts of the surrounding media, probably because of increased attenuation.
Reproducibility was assessed from eight scanning sessions that were performed 
more than one week apart both for the QRM phantom with its standardized composition and 
for the in-house-produced tubes. Using the QRM phantom, we found a low CV (~ 3% or 
less) for both the 130 HU and 90 HU threshold levels when the smallest inserts (less than 1 
mg) were used. When using saline as a surrounding medium and the in-house-produced 
phantom, CV of less than 1% was obtained, and even when using air as the surrounding 
medium, the CV was around 3% or less.
4.4 CALCIUM CONTENT—EX VIVO STUDY USING COMPUTED 
TOMOGRAPHY (STUDY IV)
In this evaluation, we used the weight of the explanted valve as the gold standard. 
The surgically explanted aortic valves were scanned by CT using the parameters that were 
determined as being found favourable in Study III. We scanned AV leaflets in saline using a 
calibration factor of 0.600 mg CaHA/cm3, a threshold value of 130 HU, a B51 reconstruction 
protocol and a slice thickness of 0.75 mm.
Ex vivo CT calcium scoring expressed as CaHA equivalent MM was compared with 
valve weight and with haemodynamic measures of aortic stenosis in terms of valve area and 
mean gradient.
The mean MM value measured by ex vivo CT was 734.4 mg CaHA for AS valves 
and 309.6 mg CaHA for AR valves (p-value <0.001), which was expected because of the 
presence of greater calcification in stenotic valves compared with incompetent ones. The CT 
CaHA MM measurements showed a very strong correlation with the total weight of the 
explanted valves (correlation coefficient, 0.91), which also allowed us to generate a 
regression equation to calculate the weight of the valve from the MM value according to: 
valve weight (g) = 0.916 + 0.002 u calcium MM (in saline). 
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Despite the good correlation observed between CT AVC MM and valve weight, 
none of these parameters showed a high correlation with the haemodynamic importance of 
the aortic valve lesion (0.39 and 0.48 for MM and 0.37 and 0.43 for weight relation with 
valve area and mean gradient). Relationships were of the same order in the BAV and TAV 
groups. The relation between mineral mass and valve weight was equally high (r = 0.91) for 
both BAV and TAV.
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5 DISCUSSION
The prognostic power of AVC regarding different cardiovascular diseases has been 
addressed in several studies over the last 15 years. In asymptomatic AS patients, AVC is a 
strong predictor of poor prognosis, with increased risk of death and need for AVR regardless 
of the severity of AS.102, 103 Many studies have reported the association between AVC as a 
disease marker and adverse clinical events in patients with cardiac diseases such as coronary 
artery disease and left ventricular hypertrophy.99, 140, 145, 146 Its importance was also addressed 
when it was shown to be a representative marker of the burden of generalized atherosclerosis 
in the body. 44, 99, 113, 140, 145, 147, 148 Thus, several studies evaluated the prognostic power of 
AVC assessment37, 102 and its ability to predict cardiovascular diseases in different patient 
populations145, 149, 150 or complications of cardiovascular procedures.151 The presence and 
burden of AVC have been linked to an increased risk of adverse results in cardiovascular 
interventions, especially in TAVR.152 In recent years, the increased number of TAVR 
procedures and the importance of AVC in predicting outcomes, particularly after procedural 
AR, have intensified the interest to study and quantify AVC in patients with AS.151, 153
Echocardiography is very useful for the preoperative evaluation and follow-up of valve 
lesions and their haemodynamic effects, as well as for the evaluation of cardiac murmurs and 
cardiac function in clinical and epidemiological settings. CT has been important to 
demonstrate the predictive value of cardiac valve calcifications and their relation to coronary 
calcium. Recently, it was stated that “it’s time to test echocardiography, an incredibly easy, 
low-cost and radiation-free method, to investigate the potential of ultrasound calcium to risk-
reclassify asymptomatic subjects”.154 To pursue such an objective, it is essential to optimize 
the diagnostic techniques—the goal of the current thesis.
5.1 ECHOCARDIOGRAPHY AND AORTIC VALVE CALCIFICATION
To our knowledge, the comparison of AVC scoring with IOS and ex vivo CT has 
not been reported. In Studies I, II and IV, we evaluated different ultrasound methods for AVC 
assessment. To quantify the echogenicity of the aortic valve, we used greyscale measurement 
software that was developed for tissue characterization of carotid artery plaques.143, 155, 156 We 
chose GSMn as a quantitative index, rather than the greyscale median, which is used 
commonly for vascular plaque characterization, because the mean value also takes small 
calcifications with high echo reflection into account. Despite the fact that it is an objective 
measure and a continuous variable, GSMn did not significantly improve the agreement in 
comparison with visual AVC scoring of the same still image, using the IOS as a gold 
standard. This was true for TTE as well as TOE images. This partly depended on the fact that 
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human visual assessment, especially for a trained investigator, has an excellent pattern-
recognition ability.156 When a single still image is used, the evaluation of the calcium burden 
depends on imaging the adequate section of the aortic leaflets. Unfortunately, the complete 
visualization of calcium content may not be possible in a single slice or transection, because 
of the irregular distribution of calcifications. The fact that an echocardiographic two-
dimensional image has a certain thickness may only partly help to correct this problem, and 
viewing the complete thickness of the valve is anticipated to provide a more accurate 
interpretation. Real-time images should therefore be more optimal, as the valve passes 
through the image in its full thickness. This should allow a more comprehensive evaluation of 
AVC throughout the whole valve. In our study, this was clearly shown as a stronger 
correlation between AVC scores and IOS for real-time images. The reproducibility of TTE 
scoring was very good (r = 0.93, p < 0.001) for real-time images, and was comparable to that 
reported by studies that used CT and Agatston score to assess AVC.153, 157, 158
Although the use of different techniques of imaging of AVC has been described in 
the literature, comparisons of the modalities and scoring systems are scarce. In general, 
echocardiographic assessment has relied on several scoring systems and indices. Total 
cardiac calcification scoring by echocardiography compares favourably to CT.145, 151 In the 
scoring system developed by Corciu et al., each leaflet receives a score of 0, 1 or 2 for 
normal, enhanced echogenicity or calcified valves, respectively, yielding a maximum 
possible score of 6 for a tricuspid valve.145 Our scoring system was rather similar, although 
we applied additional grades and calculated an average value for the whole valve, via which 
the number of leaflets (BAV or TAV) did not in itself influence the result. Another 5-grade 
scoring system was used by Tolstrup et al., in which a score of 0 denoted a normal valve, 1 
denoted slight reflectance, 2 denoted moderate reflectance, 3 denoted increased or 
generalized reflectance and 4 denoted marked reflectance with a leaflet thickness >6 mm.159,
160 In their scoring system, the highest score given to any of the leaflets represented the whole 
valve’s sclerosis score. We used the parasternal short axis view in all TTE still-image and 
real-time evaluations, to be able to visualize all aortic valve cusps in a single view. Short axis 
view images were used in a simple score by Nucifora et al., in which the aortic valve sclerosis 
score was either 0 (absent) or 1–3 (mild to severe sclerosis).149 In our 5-grade scoring system, 
a score of 1 described a normal valve, 2 indicated a thickened/sclerotic valve with no 
evidence of calcification and 3–5 denoted mildly, moderately or severely calcified valves, 
respectively (Table 5). We presumed that the evaluation of the valves by surgeons would 
allow the estimation not only of calcification, but also of thickened valve tissue without 
calcification.
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We found a better correlation between IOS and AVC in TAV compared with BAV, 
especially for still frames. This was true for both visual assessment and greyscale 
quantifications. Although the explanation of this finding is unclear, the more complex three-
dimensional structure of BAV may have contributed to the more difficult assessment, 
especially using still frames. This finding could not be compared with the results of other 
laboratories because of the lack of studies that used still images for the assessment of AVC, 
either visually or using GSM. When TOE still images were used for AVC scoring, we 
recorded results that were similar to those obtained by TTE. Thus, TOE still images did not 
yield a significantly better correlation with the gold-standard technique (IOS) for AVC visual 
scoring or for GSMn.
However, the AVC scores used for visual evaluation of real-time images obtained 
by TTE and TOE showed high correlation with IOS and correlated well with each other. This 
finding is not surprising because the aortic valve is a three-dimensional structure in which 
some areas of calcification can only be visualized in one stage of the cardiac cycle and 
disappear during other stages. As it was obvious from the initial investigations (Studies I and 
II) that the evaluation of real-time loops gave more accurate results regarding AVC scoring, 
we focused on real-time evaluations in Study IV for both TTE and TOE; for TTE, we also 
used a “global” score, meaning that the interpretations used available projections and yielded 
an overall score, instead of evaluating each leaflet and calculating an average. The 
comparison with the best easily available gold standards, i.e., weight and CT score of the 
valve, revealed no major difference between the TTE mean and global scores or the TOE 
mean score. We did not compare our results with the ashes of valves (which is a more 
cumbersome technique). Such technique has been shown to compare very well with CT MM
in carotid ex vivo comparison (with r2=0.98) and we relied on ex vivo CT for our study. 139
5.2 AORTIC VALVE PHENOTYPE
When diagnosing the presence of BAV, TOE showed higher sensitivity and 
specificity than TTE compared with surgical evaluation as a gold standard. This finding is in 
line with those of previous reports that confirmed the superiority of TOE for determining 
aortic valve morphology.161, 162 This can be attributed to the close proximity of the transducer 
to the aortic valve and improved image resolution, resulting in the high sensitivity and 
specificity of TOE.162 The presence of BAV has a high clinical significance, as it is a genetic 
disease that leads to increased risk for aortic valve lesions and complications and presentation 
of the disease almost a decade before TAV patients.121 The accuracy of the diagnosis of BAV 
can affect decision-making and treatment plans in many patients.22, 23 TOE cannot be 
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performed in all patients, but should be considered in patients with a dilated aorta and in 
cases of inconclusive TTE studies with suboptimal images in patients with suspected aortic 
pathology.
Even intra-operative recognition of BAV may be difficult. Roberts et al. noted that 
TAV is more accurately diagnosed during surgery than is BAV compared with 
histopathological evaluation. Two explanations were suggested for this finding: BAV is 
usually more calcified than TAV, and the presence of a calcified raphe can be misdiagnosed 
as a calcified border between two cusps.163
5.3 CALCIUM CONTENT — METHODOLOGICAL ASPECTS OF COMPUTED
TOMOGRAPHY
Computed tomography (CT) is an established method for the estimation of calcium 
content. Because we evaluated patients who had undergone valve replacement, it was 
possible to perform CT evaluation of the explanted valves. However, the methodological 
issues involved in such evaluation have not been described in detail. Therefore, we performed 
extensive phantom studies to determine optimal parameter settings. For this, we used two
types of phantoms to develop a standard protocol for ex vivo calcium scoring using multi-
slice CT (MSCT). Since its introduction in 1990, the reproducibility and accuracy of the 
Agatston score have been questioned because of the variable results obtained using different 
scanners and scanning parameters. This can be explained by its non-linear calculation 
algorithm and the fact that it is sensitive to noise.128, 164Among the several measurement 
modalities available (such as the modified Agatston score and the estimated calcification 
volume), here we used the CaHA equivalent mineral mass (MM), as it has been shown to be 
the most reproducible and accurate, as well as the least affected by changes in threshold, slice 
thickness and energy, and little affected by type of scanner.128-132, 139
The maximum single calcium mass that could be detected by the work station and 
software used here was between 2 and 3 g. However, a larger total amount of calcium can be 
estimated when several smaller masses are evaluated separately and summarized, even if in 
the same image. We found that using normal saline (0.9%) as the surrounding medium 
yielded the most accurate results compared with the real weight. The other media tested 
showed a systematic under-estimation of the calcium MM, regardless of slice thickness or 
calibration factor.
Both the threshold values of 90 and 130 HU yielded good results, with one 
exception, namely when 1 mm slice thickness was used with the QRM phantom, in which the 
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90 HU threshold level yielded higher values that were somewhat closer to the actual mass 
compared with the 130 HU threshold. This was in agreement with the results of previous 
studies.165, 166 However, Ferencik et al. recommended the use of the 130 HU threshold value 
for ex vivo calcium measurement,165 and a threshold value of 130 HU has been widely used 
in similar studies with good results.167, 168 The conclusion from this would be that both 90 and 
130 HU can be used.
It has been suggested that, when larger CT slice thickness is used, smaller CaHA 
inserts may be missed.165, 166 However, this was not confirmed in our phantom study, in 
which both 1 mm and 0.75 mm slice thicknesses could detect and measure all three smallest 
CaHA inserts of the QRM phantom. A smaller slice thickness could be of greater use when 
scanning ex vivo tissues in which small calcium depositions are expected to be present, such 
as vessel walls and plaques.
In our study, the use of an increased amount of the surrounding media resulted in a 
negative effect on the accuracy of MM CaHA measurements, which has also been reported 
elsewhere.139 These inferior results can probably be attributed to a higher noise and/or 
attenuation.
5.4 AORTIC VALVE CALCIFICATION — EX VIVO STUDIES
To our knowledge, this was the first study to explore ex vivo aortic valve weight and 
estimate AVC by CT MM compared with preoperative echocardiographic and intra-operative 
AVC assessment.
With the growing number of chest CT scanning events, AVC may be accidentally 
detected more often; however, it is usually overlooked and not thoroughly studied.141, 169 We 
found an excellent correlation between CT evaluation of calcium content and the weight of 
valves. This result was supported by the findings of a study that evaluated porcine plaque 
using dual-energy CT.170 Although we did not evaluate the ability to estimate AVC by in vivo 
CT scanning, it can be assumed to have an accuracy that is similar to that of the scanning of 
explanted valves in saline. Despite the better correlation between CT-evaluated calcium 
content and valve weight, the ultrasound estimation of calcium content actually correlated 
better with haemodynamic measures of the aortic lesion. In recent years, several studies have 
used CT scanning, even ex vivo, 141 to evaluate AVC and to correlate valve stenosis with the 
burden of valve calcification. 171, 172 Different brands and types of CT machines have been 
used throughout the years of CT development, including micro-CT, electron beam CT and 
MSCT machines, with up to 64-slice units.171, 173, 174 AVC scoring has been performed using 
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different methods, including the Agatston score and the modified Agatston score, volume 
scores, mass scores and even subjective scores.172, 175, 176 Aortic valve area or flow parameters 
were obtained from TTE studies, as is currently standard for AS evaluation,158, 172, 177 whereas 
TOE174 and cardiac catheterization have also been used to calculate AVA.153, 178 The results 
of these studies did not yield similar conclusions, with some showing good correlation141, 172
and others showing modest, 171 like ours, or even no correlation, 177 between AVC and the 
degree of AS. These conflicting results can be explained by discrepancies in the patient 
populations and degree of calcification. Additional calcium deposition in an already severely 
stenotic valve will most probably increase the AVC score, while it could have no or little 
effect on the AVA; similarly, essentially normal AVA can exist with variable degree of 
calcification. Good correlations between AVC MM and AVA can probably be explained by 
the inclusion of all types of valve lesions and calcification scores, including absence of 
calcification, while uniform study populations, with severe AVC and significant AS in all, 
would be expected to yield lower correlations.
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6 STRENGTHS AND LIMITATIONS 
The echocardiographic investigations were performed in a standardized manner by a 
small number of experienced investigators. TTE investigations were performed within a few 
days before the operation and the TOE was performed at the time of surgery. The evaluation 
of AVC from ultrasound images and CT measurements was performed by one investigator on 
separate occasions; moreover, this investigator was unaware of the results of the other 
modality. It is a limitation that we did not evaluate AVC by grey scale measurement in real-
time loops. The absence of in vivo preoperative CT scanning was also a limitation.
7 FUTURE PERSPECTIVES
AVC has shown prognostic importance in different cardiovascular diseases and as a 
marker of generalized atherosclerosis. In our project, we aimed to investigate different in vivo 
and ex vivo methods for quantifying AVC and relate the severity of AVC to haemodynamic 
variables of aortic valve disease and clinical risk factors. Further research is needed in this 
field involving new high-resolution imaging modalities, including molecular imaging.
In terms of two-dimensional (2-D) echocardiography future studies should focus on 
defining the state-of-the-art techniques for quantification of AVC, also at early stages. 
Continued research to develop and validate new methods for a quantitative volumetric AVC 
assessment by three-dimensional (3-D) echocardiography is mandatory. Development of 
contrast agents for molecular and cellular imaging in atherosclerosis may be of great interest 
also for aortic valve imaging. The optimal role of different imaging modalities to study AVC 
should also be determined in future studies.
New large scale prospective clinical research is needed to identify relationship 
between quantitative imaging of AVC in vivo and clinical and genetic factors. 
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8 CONCLUSIONS 
x When assessing AVC, real-time images of the aortic valve were crucial for accurate 
assessment, either using TTE or TOE.
x Using a predefined scoring system resulted in low inter- and intra-observer variability
when assessing AVC on TTE or TOE images.
x TOE was superior to TTE in determining aortic valve phenotype.
x More accurate and reproducible results can be obtained when using normal saline as the 
surrounding medium for ex vivo CT scanning for calcium scoring compared with air and 
the other surrounding media studied.
x Thinner slice thicknesses, in addition to a calibration factor of 0.600 mg CaHA/cm3 and 
threshold values of 130 HU or 90 HU, were the preferred parameters for ex vivo CT 
scanning for calcium detection in small tissue specimens.
x CaHA mineral mass measured by ex vivo CT correlated best with the ex vivo valve 
weight, whereas visual assessment of AVC using echocardiographic real-time images 
correlated better with the haemodynamic measurements of aortic valve disease.
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